Answers are grounded in this paper and cite their sources.
Investigates fish consumption impact on colorectal neoplasms in Lynch syndrome carriers, suggesting the need for further research.
BACKGROUND: Fish intake may exert anti-neoplastic effects, potentially through omega-3 fatty acids. However, its role in the development of colorectal neoplasms (CRNs) among individuals with Lynch syndrome (LS), a genetic predisposition to colorectal cancer, remains unclear. OBJECTIVES: The aim of this study was to examine the association between fish intake and CRN risk among Lynch syndrome carriers, overall and across subgroups defined by non-steroidal anti-inflammatory drug/aspirin use, sex, geographic region, CRN history, and pathogenic variant type, and to examine associations between fish types and CRN risk. METHODS: Data from 1,816 confirmed LS carriers in the GEOLynch cohort (the Netherlands) and the Colon Cancer Family Registry (Australia, Canada, USA) were used. Information on fish intake was collected at inclusion using food frequency questionnaires. CRNs included adenoma, serrated lesions, and colorectal cancer. Multivariable Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) across sex-specific quartiles and per 10 grams/day of total fish intake. Associations for specific fish types were assessed per 5 gram/day increase. RESULTS: During a median follow-up time of 7.0 years [Interquartile range: 2.8-13.6], 742 (40.9%) participants developed a CRN. The CRN risk was similar in individuals in the highest quartile of fish intake compared to the lowest quartile (HR 1.03; 95% CI: 0.81, 1.32). No association was observed for each 10 grams/day increment in fish intake (HR: 1.0; 95% CI: 0.95, 1.05) and across subgroups. However, a 5 gram/day increase in canned fish appeared to increase the risk of CRNs (HR: 1.06; 95% CI: 1.01, 1.10). CONCLUSIONS: Total fish intake does not appear to influence the development of CRNs in individuals with LS, while the influence of canned fish intake on CRN risk should be further investigated.
No takes yet. Share an insight, caveat, or question.
Bulbaai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: